Related Experiment Videos
Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571
Wei-Hua Liu1, G Mike Makrigiorgos
1Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Resistance to chronic myeloid leukemia (CML) drug STI571 has been associated with point mutations in the kinase domain of BCR-ABL. For example, the mutation T315I (g. 68721C>T) and, to a lesser extent, Y253F (g. 58796A>T) appear in a significant proportion of patients resistant to treatment. Mutations appear intimately related to the development of resistance, and they may pre-exist in a small percentage (<1%) of tumor cells at the time of treatment initiation. Most mutation detection methods, including sequencing, are unable to detect such a small percentage of mutations in a background of wild type sequences. We describe the simplification and modification of a recently developed enhanced PCR-RFLP method, and its application to the detection of T315I and Y253F mutations. The method is quantitative, can be used in agarose gel or real time PCR formats, and reliably detects 1 mutation-containing cell in a background of almost 1000 non-mutated cells. The increased sensitivity offered by this assay will allow detection of these mutations at an early stage during treatment and will be useful in rational treatment modification and in studies which address the association between these mutations and drug resistance.
Insights
A new PCR-RFLP method detects rare BCR-ABL mutations (T315I, Y253F) in chronic myeloid leukemia (CML) patients. This early detection aids in understanding drug resistance and guiding treatment modifications.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Drug resistance in chronic myeloid leukemia (CML) is often linked to BCR-ABL kinase domain mutations.
- Specific mutations like T315I and Y253F are frequently observed in patients resistant to STI571 (imatinib).
- Existing mutation detection methods struggle to identify low-frequency mutations (<1%) that may pre-exist at treatment initiation.
Purpose of the Study:
- To simplify and adapt an enhanced PCR-RFLP method for sensitive detection of T315I and Y253F mutations.
- To develop a quantitative assay capable of detecting rare mutant alleles in a wild-type background.
- To provide a tool for early identification of resistance-associated mutations in CML patients.
Main Methods:
- Modification and simplification of a previously developed enhanced PCR-RFLP technique.
- Application of the assay in both agarose gel and real-time PCR formats.
- Validation of the method's sensitivity in detecting 1 mutant cell among nearly 1000 wild-type cells.
Main Results:
- The enhanced PCR-RFLP method demonstrated high sensitivity and quantitative capabilities.
- The assay successfully detected the T315I and Y253F mutations with high accuracy.
- The method can reliably identify mutations present at a very low frequency (1 in 1000 cells).
Conclusions:
- The developed assay offers significantly increased sensitivity for detecting key BCR-ABL mutations in CML.
- Early detection of T315I and Y253F mutations can inform treatment strategies and patient management.
- This sensitive method will be valuable for research into the mechanisms of CML drug resistance.